Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
Company profile
Ticker
ARGX
Exchange
Website
CEO
Tim Van Hauwermeiren
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
argenx N.V
SEC CIK
ARGX stock data
Latest filings (excl ownership)
6-K
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years
16 Apr 24
6-K
Current report (foreign)
27 Mar 24
6-K
Current report (foreign)
27 Mar 24
6-K
Regulatory decision in Japan represents first global approval for VYVGART in ITP
26 Mar 24
20-F
2023 FY
Annual report (foreign)
21 Mar 24
6-K
Current report (foreign)
21 Mar 24
6-K
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years
8 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP
20 Feb 24
6-K
Current report (foreign)
18 Jan 24
Latest ownership filings
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G
Artisan Partners Limited Partnership
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
BlackRock Inc.
1 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 23
SC 13G/A
Artisan Partners Limited Partnership
10 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23
SC 13G
BlackRock Inc.
11 Mar 22
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
54.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 332 |
Opened positions | 73 |
Closed positions | 29 |
Increased positions | 134 |
Reduced positions | 95 |
13F shares | Current |
---|---|
Total value | 15.83 tn |
Total shares | 32.25 mm |
Total puts | 196.60 k |
Total calls | 588.40 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
FMR | 4.96 mm | $2.44 tn |
T. Rowe Price | 3.66 mm | $1.80 tn |
Artisan Partners Limited Partnership | 2.83 mm | $1.39 tn |
Jennison Associates | 1.51 mm | $743.22 bn |
JHG Janus Henderson | 1.47 mm | $723.26 bn |
Capital World Investors | 1.43 mm | $703.50 bn |
Avoro Capital Advisors | 1.00 mm | $491.63 bn |
BLK Blackrock | 992.20 k | $487.79 bn |
T. Rowe Price Investment Management | 966.36 k | $474.00 bn |
BLVGF Bellevue | 911.53 k | $448.14 bn |
News
argenx Data Shows Evidence That VYVGART And VYVGART Hytrulo Deliver Transformative Results For Patients Suffering From Debilitating Autoimmune Diseases
16 Apr 24
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
10 Apr 24
HC Wainwright & Co. Maintains Buy on argenx, Maintains $451 Price Target
27 Mar 24
argenx Announces Plan To Continue The Development Of Efgartigimod Primary Sjogren's Disease
27 Mar 24
Key Takeaways From argenx Analyst Ratings
26 Mar 24
Press releases
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
16 Apr 24
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
28 Mar 24
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
27 Mar 24
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
26 Mar 24
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
26 Mar 24